Ginkgo Bioworks Holdings第四季度EPS为$(2.00),未达到预期$(1.77),销售额为4385万美元,未达到预期的4446万美元

财报速递
26 Feb
Ginkgo Bioworks Holdings (NYSE:DNA)报告的季度每股亏损为$(2.00),低于分析师普遍预期的$(1.77),差距为12.99%。相比去年同期每股亏损$(4.28),这是53.27%的改善。该公司本季度报告销售额为4385万美元,未达到分析师普遍预期的4446万美元,差距为1.39%。相比去年同期的3476万美元,这一数据增长了26.16%。

以上内容来自Benzinga Earnings专栏,原文如下:

Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(2.00) per share which missed the analyst consensus estimate of $(1.77) by 12.99 percent. This is a 53.27 percent increase over losses of $(4.28) per share from the same period last year. The company reported quarterly sales of $43.85 million which missed the analyst consensus estimate of $44.46 million by 1.39 percent. This is a 26.16 percent increase over sales of $34.76 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10